As Asian markets navigate through a period of trade discussions and economic adjustments, investors are keenly observing opportunities that may arise from the ongoing shifts in global trade policies. In this context, identifying stocks that might be trading below their estimated value can provide potential avenues for growth, especially as these market dynamics continue to evolve.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| DigiPlus Interactive (PSE:PLUS) | ₱45.50 | ₱89.72 | 49.3% |
| Aidma Holdings (TSE:7373) | ¥1924.00 | ¥3717.62 | 48.2% |
| Ficont Industry (Beijing) (SHSE:605305) | CN¥27.06 | CN¥52.64 | 48.6% |
| Hunan SUND Technological (SZSE:301548) | CN¥48.09 | CN¥95.24 | 49.5% |
| Sanil Electric (KOSE:A062040) | ₩60700.00 | ₩119171.75 | 49.1% |
| Boditech Med (KOSDAQ:A206640) | ₩16010.00 | ₩31114.67 | 48.5% |
| Hangzhou SF Intra-city Industrial (SEHK:9699) | HK$10.00 | HK$19.68 | 49.2% |
| Dive (TSE:151A) | ¥936.00 | ¥1850.73 | 49.4% |
| Taiyo Yuden (TSE:6976) | ¥2380.00 | ¥4629.13 | 48.6% |
| BrightGene Bio-Medical Technology (SHSE:688166) | CN¥50.60 | CN¥98.57 | 48.7% |
We're going to check out a few of the best picks from our screener tool.
Giant Biogene Holding (SEHK:2367)
Overview: Giant Biogene Holding Co., Ltd. is an investment holding company that designs, develops, and manufactures skin treatment products with recombinant collagen in the People’s Republic of China, with a market cap of HK$87.28 billion.
Operations: The company's revenue primarily comes from the research, development, manufacture, and sale of bioactive material-based beauty and health products, amounting to CN¥5.54 billion.
Estimated Discount To Fair Value: 20.9%
Giant Biogene Holding appears undervalued based on cash flows, trading at HK$82.45, below its estimated fair value of HK$104.29. Recent earnings growth of 42.1% and expected annual profit growth of 20.52% highlight robust financial health, despite significant insider selling in the past quarter. The company completed a follow-on equity offering raising HKD 2.33 billion and announced dividends for 2024, reinforcing its commitment to shareholder returns amidst strong revenue forecasts exceeding market averages.
- Our expertly prepared growth report on Giant Biogene Holding implies its future financial outlook may be stronger than recent results.
- Take a closer look at Giant Biogene Holding's balance sheet health here in our report.
Hangzhou SF Intra-city Industrial (SEHK:9699)
Overview: Hangzhou SF Intra-city Industrial Co., Ltd. is an investment holding company that offers intra-city on-demand delivery services in the People's Republic of China, with a market cap of HK$9.14 billion.
Operations: The company generates revenue of CN¥15.75 billion from its intra-city on-demand delivery service business in the People's Republic of China.
Estimated Discount To Fair Value: 49.2%
Hangzhou SF Intra-city Industrial is trading at HK$10, significantly below its fair value estimate of HK$19.68, suggesting undervaluation based on cash flows. The company reported a substantial increase in net income to CNY 132.46 million for 2024 from CNY 50.6 million the previous year, with earnings per share doubling to CNY 0.15. Analysts expect earnings growth of 42.8% annually over the next three years, surpassing market averages and indicating strong future performance potential despite low forecasted return on equity.
- Our growth report here indicates Hangzhou SF Intra-city Industrial may be poised for an improving outlook.
- Dive into the specifics of Hangzhou SF Intra-city Industrial here with our thorough financial health report.
Asia Vital Components (TWSE:3017)
Overview: Asia Vital Components Co., Ltd. specializes in providing thermal solutions globally and has a market cap of NT$218.27 billion.
Operations: The company generates revenue primarily through its Overseas Business Department, contributing NT$81.45 billion, and its Integrated Management Division, adding NT$54.67 billion.
Estimated Discount To Fair Value: 18.6%
Asia Vital Components is trading at NT$563, below its fair value of NT$692.07, indicating potential undervaluation based on cash flows. Recent earnings show significant growth, with Q1 2025 net income reaching TWD 3.51 billion from TWD 1.75 billion a year ago. Analysts forecast revenue to grow at 21.3% annually and earnings by 24.6%, both outpacing market averages, despite recent share price volatility and only moderate undervaluation relative to fair value estimates.
- Our earnings growth report unveils the potential for significant increases in Asia Vital Components' future results.
- Click here to discover the nuances of Asia Vital Components with our detailed financial health report.
Seize The Opportunity
- Navigate through the entire inventory of 271 Undervalued Asian Stocks Based On Cash Flows here.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Looking For Alternative Opportunities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Asia Vital Components might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com